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    Abstract:   Disrupted synchronized oscillatory fi  ring of pyramidal neuronal networks in the cerebral cortex in the gamma frequency band 
(i.e., 30  –  100 Hz) mediates many of the cognitive defi  cits and symptoms of schizophrenia. In fact, the density of dendritic spines and 
the average somal area of pyramidal neurons in layer 3 of the cerebral cortex, which mediate both long-range (associational) and local 
(intrinsic) corticocortical connections, are decreased in subjects with this illness. To explore the molecular pathophysiology of pyramidal 
neuronal dysfunction, we extracted ribonucleic acid (RNA) from laser-captured pyramidal neurons from layer 3 of Brodmann  ’  s area 
42 of the superior temporal gyrus (STG) from postmortem brains from schizophrenia and normal control subjects. We then profi  led the 
messenger RNA (mRNA) expression of these neurons, using microarray technology. We identifi  ed 1331 mRNAs that were differentially 
expressed in schizophrenia, including genes that belong to the transforming growth factor beta (TGF-  β  ) and the bone morphogenetic 
proteins (BMPs) signaling pathways. Disturbances of these signaling mechanisms may in part contribute to the altered expression 
of other genes found to be differentially expressed in this study, such as those that regulate extracellular matrix (ECM), apoptosis, 
and cytoskeletal and synaptic plasticity. In addition, we identifi  ed 10 microRNAs (miRNAs) that were differentially expressed in 
schizophrenia; enrichment analysis of their predicted gene targets revealed signaling pathways and gene networks that were found by 
microarray to be dysregulated, raising an interesting possibility that dysfunction of pyramidal neurons in schizophrenia may in part 
be mediated by a concerted dysregulation of gene network functions as a result of the altered expression of a relatively small number 
of miRNAs. Taken together, fi  ndings of this study provide a neurobiological framework within which specifi  c hypotheses about the 
molecular mechanisms of pyramidal cell dysfunction in schizophrenia can be formulated.   
  Keywords:    cerebral  cortex  ,    gene  expression  proﬁ   ling  ,    laser-capture  microdissection  ,    microRNA  ,    schizophrenia   
  INTRODUCTION 
  Gray matter volume in the cerebral cortex has been 
consistently found to be decreased in patients with 
schizophrenia (Ananth et     al., 2002; Wilke et     al., 2001). 
The superior temporal gyrus (STG) is one of the corti-
cal regions that exhibit the most pronounced volumetric 
reduction (McCarley et     al., 1999; Yamasue et     al., 2004). 
This reduction is thought to reﬂ  ect a decrease in the num-
ber of synapses (Selemon   &   Goldman-Rakic, 1999), the 
majority of which appear to be located on the dendritic 
spines of pyramidal neurons (Glantz   &   Lewis, 2000; 
Sweet et     al., 2009). 
  Pyramidal neurons in the cerebral cortex exhibit 
layer-speciﬁ   c connectional properties, providing neu-
ral circuit architectures that support distinct aspects of 
higher cortical functions. For instance, dendritic spines 
on pyramidal neurons in layer 3 are targeted by both local 
and long-range glutamatergic projections in a highly 
reciprocal fashion. Synchronized activities of pyramidal 
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neuronal networks through these connections, especially 
in the gamma frequency band (i.e., 30  –  100 Hz), are criti-
cal for the integrity of higher cortical functions (Buzsaki  &  
Draguhn, 2004). Disturbances of these networks may con-
tribute to the pathophysiology of schizophrenia by com-
promising gamma oscillation (Arnsten et     al., 2010; Lewis 
  &   Gonzalez-Burgos, 2008; Uhlhaas   &   Singer, 2010). This 
concept is supported by the following postmortem and 
clinical observations. First, the density of dendritic spines 
on pyramidal neurons in layer 3 of the cerebral cortex, 
including the STG, have been shown to be decreased by 
23 – 66% in subjects with schizophrenia (Costa et   al., 2001; 
Garey et     al., 1998; Glantz   &   Lewis, 2000; Sweet et     al., 
2009). Second, consistent with these ﬁ  ndings, the aver-
age somal area of these pyramidal cells is signiﬁ  cantly 
smaller (Sweet et     al., 2003, 2004). Third, in the prefrontal 
cortex, the density of glutamatergic axonal boutons, of 
which dendritic spines are their major targets, was sig-
niﬁ  cantly decreased by as much as 79% in layer 3 (but 
not in layer 5) in subjects with schizophrenia (Bitanihirwe 
et     al., 2009). Finally, an increasing number of clinical 
studies have consistently demonstrated that gamma oscil-
latory synchrony is impaired in patients with schizophre-
nia (Cho et     al., 2006; Kwon et     al., 1999; Spencer et     al., 
2004; Uhlhaas   &   Singer, 2010). Furthermore, gamma 
impairment has been linked to the symptoms and cogni-
tive deﬁ  cits of the illness, and their severity has in turn 
been associated with the magnitude of cortical gray mat-
ter reduction (Cascella et     al., 2010; Gur et     al., 1999, 2000; 
Mitelman et     al., 2003; Suga et     al., 2010). Taken together, 
understanding the molecular underpinnings of pyramidal 
cell functional impairment will shed important light onto 
the pathophysiology and thereby the conceptualization 
of novel and rational treatment of cortical dysfunction in 
schizophrenia. 
  In order to identify the molecular correlates of pyra-
midal cell dysfunction in schizophrenia, we combined 
laser-capture microdissection (LCM) with Affymetrix 
microarray and high-throughput TaqMan-based MegaPlex 
quantitative reverse transcriptase  –  polymerase chain reac-
tion (qRT-PCR), respectively, to elucidate the alterations 
in messenger RNA (mRNA) and microRNA (miRNA) 
expression proﬁ  les of these neurons in layer 3 of the STG. 
We found that transforming growth factor beta (TGF-  β ) 
and bone morphogenetic protein (BMP) signaling path-
ways and many genes that regulate extracellular matrix 
(ECM), apoptosis and cytoskeleton were dysregulated 
in schizophrenia. In addition, we identiﬁ  ed 10 differen-
tially expressed miRNAs; the predicted targets of which 
included the dysregulated pathways and gene networks 
identiﬁ   ed by microarray analysis. Together these ﬁ  nd-
ings provide a conceptual framework within which we 
can begin to formulate and test speciﬁ  c hypotheses of the 
neurobiological mechanisms that underlie pyramidal cell 
dysfunction in schizophrenia.     
  MATERIALS AND METHODS   
  Postmortem Human Brain Tissue 
  Liquid nitrogen vapor fresh-frozen blocks, approximately 
3 mm thick and containing the STG (Brodmann  ’  s area 42), 
matched for age, sex, pH, and postmortem interval (PMI) 
(Table 1), were obtained from the Harvard Brain Tissue 
Resource Center (HBTRC) at McLean Hospital, Belmont, 
Massachusetts. Postmortem human brain collection proce-
dures of the HBTRC, including the informed consent pro-
cess, have been approved by the Partners Human Research 
Committee. Written informed consent for use of each 
of the brains for research has been obtained by the legal 
next of kin. All of the brains included in this study were 
examined by a Board-certiﬁ  ed neuropathologist to rule out 
any neurological disorders. In addition, the fact that none 
of the subjects had any active history of substance abuse 
or dependence was conﬁ  rmed by toxicological analysis. 
A detailed methodology for tissue preparation, LCM and 
RNA processing has been described in detail elsewhere 
(Pietersen et     al., 2009, 2011).    
 LCM 
 Sections of 8  μ m were cut on a cryostat, mounted on slides 
and stored at            8 0  °  C until use. Pyramidal neurons were 
stained with the Histogene     quick staining kit (Applied 
Biosystems, Foster City, CA) and identiﬁ   ed based on 
the pyramidal morphology and the clearly identiﬁ  able 
proximal apical and basal dendrites (Figure 1). In addi-
tion, pyramidal neurons that were in close proximity to 
any nonpyramidal cells were excluded in order to avoid 
cellular contamination. Pyramidal neurons were removed 
using the Arcturus XT system (Applied Biosystems). 
Approximately 500 neurons per subject were captured 
onto a CapSure HS LCM cap (Applied Biosystems) for the 
microarray experiment whereas approximately 100 cells 
were captured for miRNA proﬁ  ling. To avoid systematic 
biases, samples from schizophrenia and normal control 
subjects were processed for LCM in a random order.     
 Affymetrix  Platform – Based  Microarray  Gene 
Expression Proﬁ  ling   
 RNA  Processing 
  RNA isolation was performed using the Picopure RNA 
isolation kit (Life Technologies, Grand Island, NY), with 
a DNase step (Qiagen, Valencia, CA). This typically 
resulted in approximately 1  –  25 ng of total RNA (Table 2) 
(Pietersen et     al., 2009, 2011). Total RNA integrity was 
evaluated by RNA Quality Indicator (RQI) generated Pyramidal Neurons in Schizophrenia  55
   Table 1.   Subjects included in this study.   
Group Sex  a Age  b PMI  c  pH Smoker Cause of death Antipsychotic  d 
Control F 79 15.00 6.59 Yes Cardiac arrest N/A
Control M 22 21.47 6.75 Yes Myocardial infarction N/A
Control M 75 20.25 6.35 Yes Unknown N/A
Control M 80 15.50 6.26 Yes Myocardial infarction N/A
Control F 58 21.08 6.79 No Myocardial infarction N/A
Control M 61 17.00 6.64 Yes Unknown N/A
Control F 71 20.50 6.89 Unknown Unknown N/A
Control F 90 12.66 6.10 Unknown Lung cancer N/A
Control F 86 6.92 5.74 Unknown Myocardial infarction N/A
Mean      SEM 4M/5F 69.11        6.85 16.71        1.60 6.46        0.12
Schizophrenia F 93 6.92 6.13 Unknown Renal failure Perphenazine (50)
Schizophrenia M 55 21.40 6.51 Yes Myocardial infarction Perphenazine
Schizophrenia F 67 21.80 5.80 Unknown Pulmonary disease Thioridazine, 
prochlorperazine (200)
Schizophrenia F 55 22.00 5.90 Yes Cancer Clozapine, olanzapine
Schizophrenia M 36 17.97 6.45 Unknown Cardiac arrest Clozapine (350)
Schizophrenia M 62 10.75 6.50 Yes Chronic obstructive pulmonary 
disease, lung cancer
Clozapine
Schizophrenia F 92 17.80 6.34 Unknown Cardiomyopathy Unknown
Schizophrenia M 56 21.83 6.75 No Car accident Olanzapine (150)
Schizophrenia F 88 13.33 6.65 No Unknown Thiothixene (50)
Mean      SEM 4M/5F 68.11        6.60 16.90        1.85 6.34        0.11
    a F        female;  M        male.   
  b  Age is given in years.     
  c PMI        postmortem  interval  in  hours.   
  d N/A           not applicable; numbers in parentheses indicate CED.     
by the Experion HighSens LabChip (Bio-Rad, Hercules, 
CA), although in a minority of cases the amount of total 
RNA was too small for this analysis (Table 2). 
 RNA extracted from laser-captured neurons underwent 
two rounds of linear ampliﬁ  cation using the RiboAmp kit 
(Life Technologies) to obtain ampliﬁ  ed (a)RNA. A dilution 
of the resulting products (approximately 250 ng/  μ L)  was 
used to determine the distribution of transcript lengths with 
the Experion StdSens Labchip (Bio-Rad; Figure 1). The 
concentration and purity of these samples were determined 
by absorbance measurements at the optical density of A260 
and A280, using a NanoDrop spectrophotometer (Thermo 
Scientiﬁ  c, Tewksbury, MA) (Table 2).    
  Microarray and qRT-PCR Validation 
  The TURBO Biotin labeling kit (end-labeling; Life 
Technologies) was used to label the aRNA obtained from 
ampliﬁ  ed samples (  ∼ 15   μ  g). Gene expression proﬁ  ling was 
performed using the Affymetrix Human X3P GeneChip    ®   , 
which possesses an extreme 3  ’   bias in its probe design and 
hence is particularly suitable for samples that are prone to 
RNA degradation, such as postmortem human brain tissue. 
This chip has also been shown to be superior to the more 
commonly used Affymetrix human U133 plus 2.0 chip 
in terms of data reproducibility (Caretti et     al., 2008). The 
hybridization and scanning procedures were performed at 
the Partners HealthCare Center for Personalized Genetic 
Medicine, Cambridge, Massachusetts. Brieﬂ  y, target label-
ing was performed using the Message-AMP Biotin Enhanced 
Kit (Life Technologies). Fifteen micrograms of biotinylated 
RNA was fragmented, hybridized to GeneChips, stained 
with two rounds of streptavidinphycoerythrin (Molecular 
Probes, Eugene, OR) and one round of biotinylated anti-
streptavidin antibody (Vector Laboratories, Burlingame, 
CA), scanned twice, and inspected for hybridization arti-
facts before proceeding to data normalization and analysis. 
  For validation of microarray data, cDNA was reverse 
transcribed from aRNA (200 ng input) using the High 
Capacity RNA-to-cDNA kit (Applied Biosystems). 
TaqMan    ®    -based qRT-PCR (Applied Biosystems) was sub-
sequently performed on selected differentially expressed 
genes within signaling pathways identiﬁ  ed by pathway anal-
ysis as dysregulated in schizophrenia and several randomly 
chosen genes (Supplementary Table 1; available online at 
http://informahealthcare.com/doi/abs/10.3109/01677063.
2014.882918). Samples were normalized with respect to the 
housekeeping gene, hypoxanthine guanine phosphoribo-
syltransferase (HPRT), which has been shown to produce 
reliable results in human brain tissue as its expression does 
not appear to differ in disease states (Radonic et     al., 2004). 
Normalization was performed against only one gene because 
of the limited quantity of RNA available from laser-captured 
samples. Negative controls (negative reverse transcription 56  C. Y. Pietersen et al.
and no template controls) were performed to detect any con-
tamination of the samples, such as genomic (g)DNA. Where 
necessary, samples were treated with Turbo DNA-free kit 
(Applied Biosystems) and the negative controls repeated to 
conﬁ  rm gDNA removal before qRT-PCR was performed. 
Samples were run in duplicate. If the difference between the 
duplicates exceeded 0.5 C  t   (threshold cycle), the samples 
were repeated. The average of the duplicates was taken as 
input for quantiﬁ  cation using the 2      Δ C  
t    method (Livak   &   
Schmittgen, 2001) or the relative expression software tool 
(REST) for group-wise comparisons of expression ratios 
(Pfafﬂ   et     al., 2002). A Spearman  ’  s rho correlation analy-
sis was then performed on the fold-changes determined by 
microarray and qRT-PCR. In accordance with Morey et     al. 
(2006), a correlation of           0.8  with  a  signiﬁ  cance of p       0.05 
between qRT-PCR and microarray expression changes was 
considered validation of the microarray result.     
 miRNA  Proﬁ  ling Using Megaplex miRNA 
TaqMan Arrays 
  Total RNA was extracted from   ∼ 100  laser-captured 
cells with the   mir  Vana miRNA Detection Kit (Life 
Technologies). This typically resulted in approximately 
4  –  7 ng of total RNA (Table 2). The concentration and 
purity of the total RNA were determined by a NanoDrop 
spectrophotometer, as described above. miRNA proﬁ  l-
ing was conducted according to manufacturer  ’  s speci-
ﬁ  cations (Supplementary Methods 1 available online at 
http://informahealthcare.com/doi/abs/10.3109/01677063.
2014.882918).   
 Data  Analysis  
 Microarray  Data Analysis 
  Each array was scanned twice and the Affymetrix 
Microarray Suite 5.1 software averaged the two images 
to compute an intensity value for each probe cell within 
each probe set. For the quality control step, we employed 
the dChip and Partek software  ’  s built-in function (Partek, 
St. Louis, MO). We then normalized the data with 
Partek  ’  s standard normalization method (i.e., data have a 
mean of 0 and a variance of 1, and each column for each 
sample was divided by the average of all control samples). 
Principal component analysis revealed the contribution 
  Figure 1.      Identiﬁ  cation of pyramidal neurons and LCM procedure. Photomicrograph of a pyramidal neuron in the STG visualized with 
Histogene    stain  ( A  ). After identiﬁ  cation (  B  ), pyramidal neurons are captured (  C  ) onto the LCM cap (  D ).  ( E  ) Representative virtual gels 
showing the distribution of sizes of ampliﬁ  ed products after two rounds of linear ampliﬁ  cation of RNA extracted from   ∼ 500  pyramidal 
neurons from a normal control (C) and a schizophrenia (S) subject. L            ladder.  ( F  ) Heatmap of 1331 differentially expressed genes 
identiﬁ  ed based on the stringency criteria of fold-change           1.1  and  FDR-corrected  p        0.05.  Scale  bars        25   μ m.  Pyramidal Neurons in Schizophrenia  57
of batch effect (i.e., scan date), but not sex, age, PMI, 
or antipsychotic treatment, to the observed expression 
variance. As such, an analysis of covariance (ANCOVA) 
was performed with batch effect as covariate (Simunovic 
et     al., 2009). Differentially expressed genes were visual-
ized by performing unsupervised hierarchical clustering 
as stringency of the ﬁ   ltering criteria (i.e., fold-change 
and false discovery rate [FDR]-adjusted p-value) was 
varied to determine a representative gene list for pathway 
analyses. 
  We employed three approaches to explore the bio-
logical signiﬁ  cance of our expression data. First, dif-
ferentially expressed genes were manually grouped to 
elucidate gene families that were dysregulated in schizo-
phrenia. Second, pathway analyses were performed with 
two Web-based algorithms,   Ingenuity Pathway Analysis  
(Ingenuity Systems, Redwood City, CA) and   MetaCore  
(GeneGo, Carsbad, CA), to map the differentially 
expressed genes onto biological functions and canoni-
cal pathways. With   Ingenuity  , the signiﬁ  cance for each 
of the identiﬁ  ed pathways was determined via a Fisher  ’  s 
exact test, whereas GeneGo   Metacore   makes use of their 
algorithm for hypergeometric distribution, identifying 
pathways overrepresented with signiﬁ  cant genes. Third, 
literature mining was performed to elucidate which of 
these pathways or gene families might be particularly 
pertinent for pyramidal neuronal functions and dendritic/
synaptic architecture and plasticity. We also made note 
of differentially expressed genes that have been impli-
cated as schizophrenia risk genes (Allen et     al., 2008). 
Microarray data have been deposited into the Gene 
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.
gov/projects/geo/; accession number GSE37981).     
 miRNA  Data Analysis 
 Primary analysis of the acquired signal data was performed 
in SDS and RQ Manager (Applied Biosystems). Quality 
control and differential expression analyses were performed 
using the qRT-PCR package for miRNA arrays (Applied 
Biosystems) in Bioconductor (www.bioconductor.org). 
The databases used to identify potential miRNA targets 
for speciﬁ  c miRNAs are summarized in Supplementary 
Methods 2 available online at http://informahealthcare.
com/doi/abs/10.3109/01677063.2014.882918.  Signiﬁ  cant 
enrichment of speciﬁ  c Gene Ontology categories or KEGG 
(Kyoto Encyclopedia of Genes) pathways was estimated 
by hypergeometric tests or chi-square tests. Enriched path-
ways overrepresented by potential miRNA target genes 
were then determined with the p-value obtained by hyper-
geometric tests and adjusted for multiple comparisons 
(Kanehisa   &   Goto, 2000; Kanehisa et     al., 2006, 2010).      
   Table 2.   RNA quantity and quality.   
Group
RIN of total RNA extracted 
from homogenized cortex  a 
Microarray samples
Number of 
cells captured
Total RNA 
RQI  b 
Amount of RNA before/
after ampliﬁ  cation (  μ g) A260/A280
Control 8.2 510 2.6 0.025/39.50 2.67
Control 7.9 530 N/A 0.004/69.30 2.37
Control 8.9 520 3.1 0.014/54.30 2.44
Control 8.8 500 2.8 0.004/39.49 2.51
Control 7.8 680 3.4 0.007/50.10 2.39
Control 9 600 3.7 0.009/59.92 2.54
Control 8.4 530 2.8 0.012/39.60 2.47
Control 8 520 3.6 0.007/29.83 2.75
Control 8.8 520 N/A 0.002/24.52 2.70
Mean      SD 8.42        0.15 545.56        19.30 3.14        0.16 0.009        0.002/40.73        5.15 2.54        0.05
Schizophrenia 8.9 525 3.8 0.004/76.83 2.47
Schizophrenia 8 525 4.2 0.003/65.10 2.43
Schizophrenia 7.9 540 N/A 0.002/62.10 2.52
Schizophrenia 8.5 540 2.8 0.004/46.92 2.75
Schizophrenia 9.2 530 N/A 0.001/62.10 2.44
Schizophrenia 8.5 630 N/A 0.002/75.90 2.34
Schizophrenia 8.2 540 3.5 0.003/65.68 2.50
Schizophrenia 8.8 700 3.4 0.003/50.10 2.47
Schizophrenia 8.4 550 3.4 0.003/52.20 2.47
Mean      SD 8.48        0.16 564.56        20.06 3.52        0.19 0.002        0.0003/61.88        3.54 2.49        0.04
    a  RNA integrity number (RIN) of total RNA extracted from homogenized gray matter determined by an Agilent 
bioanalyzer.   
  b  RNA Quality Indication (RQI) of total RNA extracted from laser-captured neurons determined by a BioRad Experion 
Automated Electrophoresis System. N/A              not available: total RNA concentration too low to determine RQI.     58  C. Y. Pietersen et al.
 RESULTS  
  Affymetrix-Based Microarray Gene Expression 
Proﬁ  ling 
  We evaluated the reliability of our ﬁ  ndings by assessing 
mRNA quality based on a combination of metrics, as 
there is not a single parameter that can serve as the sole 
determinant or predictor of mRNA quality. Although the 
quality of the total RNA extracted from homogenized cor-
tex from all of the subjects used in this study appears to 
be superb (Table 2), the RQI of most samples on average 
tended to be relatively low, suggesting some RNA degra-
dation. This was expected given the signiﬁ  cantly lengthier 
(i.e., compared with extracting RNA from homogenized 
tissue) aqueous steps required for RNA extraction from 
single neurons (Pietersen et     al., 2009, 2011). However, 
although RQI is a measure of total RNA integrity, it does 
not necessarily predict the quality of mRNA, which con-
stitutes only 1  –  3% of total RNA (Vermeulen et     al., 2011). 
In fact, virtual gels of the ampliﬁ  ed products generated 
after two rounds of linear ampliﬁ  cation of RNA extracted 
from pyramidal neurons revealed very healthy spreads of 
transcript lengths, extending well into the 5  –  6 kb range 
(Figure 1). Furthermore, the efﬁ   ciency of microarray 
hybridization appeared to be adequate in terms of probe 
intensity and percentage of present calls, and these param-
eters were highly comparable between the schizophrenia 
and control groups, with average (     SD) probe intensity 
being  81.8        10.5  and  70.7        6.2,  respectively,  and  per-
cent present calls 26.9           2.6  and  27.5        1.0,  respectively. 
Overall, these percentages of present calls are lower than 
what have been reported in previously published schizo-
phrenia microarray studies performed on RNA extracted 
from homogenized cortical gray matter (typically in the 
range of 40  –  45%), which contains a much greater num-
ber of RNA species in much larger quantities. Our data, 
however, are similar in magnitude to what was reported in 
a recent microarray study of laser-dissected hippocampal 
subﬁ  elds in humans (mean      SD        31.8        4.9)  (Benes 
et     al., 2008), a region that is cellularly much less hetero-
geneous than cortical gray matter but more so than our 
neuronal samples, and to what was described in previous 
microarray studies based on laser-captured cells from 
clinical samples or other specimens of single cells (Luzzi 
et     al., 2001; Mahadevappa   &   Warrington, 1999). 
  Varying the stringency criteria of fold-change and 
FDR-adjusted p-value resulted in several lists of differen-
tially expressed genes (Supplementary Table 2 available 
online at http://informahealthcare.com/doi/abs/10.3109/
01677063.2014.882918). For instance, 1331 genes were 
identiﬁ  ed based on the criteria of a minimal fold-change of 
1.1 and p          0.05, whereas only 264 genes met the slightly 
more stringent criteria of fold-change of 1.2 and p       0.05. 
As a result, the 1331 genes were used for downstream 
pathway analysis. Hierarchical clustering revealed that 
these 1331 genes appeared to be well segregated accord-
ing to diagnosis (Figure 1). A complete list of these genes 
is shown in Supplementary Table 3 available online at 
http://informahealthcare.com/doi/abs/10.3109/01677063.
2014.882918. The canonical pathways and functional 
gene networks that were found to be altered in schizophre-
nia included the TGF-  β  /BMP signaling cascades, genes 
that regulate cytoskeleton and dendritic morphology and 
ECM composition, in addition to changes in apoptosis and 
DNA damage canonical pathways (Tables 3a  –  d). A num-
ber of key genes within the pathways that were found to 
be signiﬁ  cantly differentially regulated in schizophrenia 
(  N            6) and several randomly selected genes (  N         4)  were 
quantiﬁ  ed by qRT-PCR; the expression levels of these 
genes were signiﬁ  cantly correlated with the microarray 
data (p          0.003; Figure 2). HPRT expression level also did 
not differ between schizophrenia and normal control 
groups (Supplementary Figure 1 available online at 
http://informahealthcare.com/doi/abs/10.3109/0167706
3.2014.882918).  Finally, correlation analyses between 
the expression of the validated genes and age, PMI, and 
chlorpromazine equivalent dosage (CED) revealed no 
association of gene expression changes with any of these 
parameters, consistent with PCA results showing that 
none of these parameters appear to signiﬁ  cantly contrib-
ute to differential gene expression variance of the entire 
data set. A representative correlation with   SMAD4   (signal 
via the mothers against decapentaplegic homologs 4), the 
key transcription factor upon which TGF-  β   and BMP sig-
naling cascades converge, is depicted in Supplementary 
Figure 2 available online at http://informahealthcare.com/
doi/abs/10.3109/01677063.2014.882918.  
 TGF- β   Superfamily Signaling Is Altered in Schizophrenia 
 The TGF- β  superfamily of proteins consists of over thirty 
members (Derynck  &  Miyazono, 2008). Structurally they 
can be subdivided in three subfamilies: TGF-  β ,  inhibins, 
and other proteins including BMPs and growth and dif-
ferentiation factor (GDF). Together these proteins are 
involved in very diverse and complex cellular functions 
in both developing and adult systems, including the brain 
(Benes, 2011; Derynck   &   Miyazono, 2008; Massague   &   
Gomis, 2006; Vivien  &  Ali, 2006). We found that the TGF- β  
and BMP signaling canonical pathways were highly dys-
regulated in schizophrenia (  GeneGo :  p        0.0001),  with 
up-regulation of several genes immediately downstream 
from the TGF-  β  1 receptor (Supplementary Table 3a, 
Figure 3 available online at http://informahealthcare.
com/doi/abs/10.3109/01677063.2014.882918; Figure 3). 
This is in line with a previous postmortem study reveal-
ing an up-regulation of the TGF-  β   signaling cascade in 
the hippocampus of schizophrenia subjects (Benes et     al., 
2007) and is consistent with previous reports showing the Pyramidal Neurons in Schizophrenia  59
   Table 3a.   Signiﬁ  cantly affected genes within TGF-  β  /BMP signaling pathway.   
Gene title Gene symbol p-Value
Fold-change 
(S vs. C)  a 
bone morphogenetic protein 1 BMP1 0.04       1.33
bone morphogenetic protein receptor, type IA BMPR1A 0.04 1.19
bone morphogenetic protein 5 BMP5 0.04 1.16
bone morphogenetic protein 7 BMP7 0.03 1.21
caveolin 1, caveolae protein, 22 kDa CAV1 0.03 1.54
CREB-binding protein CBP 0.01 1.31
growth arrest and DNA-damage-inducible, beta GADD45B 0.03 1.30
mitogen-activated protein kinase kinase 6 MEK6 0.04       1.14
ribosomal protein S6 kinase, 90kDa, polypeptide 5 RPS6KA5 0.01 1.11
SHC (Src homology 2 domain containing)-transforming protein 1 SHC1 0.03 1.16
SMAD family member 4 SMAD4 0.01 1.19
SMAD family member 5 SMAD5 0.02 1.48
SKI-like oncogene SKIL 0.02       1.15
transcription factor speciﬁ  city protein 1 SP1 0.03 1.29
X-linked inhibitor of apoptosis XIAP 0.02 1.10
zinc ﬁ  nger, FYVE domain containing 9 ZFYVE9/SARA 0.04 1.14
    a S        schizophrenia;  C        control.   
   Table 3b.   Signiﬁ  cantly affected genes associated with extracellular matrix.   
Gene title Gene symbol p-Value
Fold-change 
(S vs. C)  a 
aggrecan ACAN 0.03       1.26
ADAM metallopeptidase with thrombospondin type 1 motif, 1 ADAMTS1 0.03 2.56
ADAM metallopeptidase with thrombospondin type 1 motif, 6 ADAMTS6 0.05 1.15
hyaluronan and proteoglycan link protein 1 HAPLN1 0.05       1.14
leucine proline-enriched proteoglycan (leprecan) 1 LEPRE1 0.04       1.21
lumican LUM 0.03       1.12
matrix metallopeptidase 16 (membrane-inserted) MMP16 0.02       1.17
matrix metallopeptidase 25 MMP25 0.02       1.14
matrix metallopeptidase 24 (membrane-inserted) MMP24 0.01 1.22
sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) SPAM1 0.04 1.15
sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 SPOCK3 0.01 1.11
spondin 1, extracellular matrix protein SPON1 0.02 2.14
versican VCAN 0.04       1.13
    a S        schizophrenia;  C        control.   
   Table 3c.   Signiﬁ  cantly affected genes associated with apoptosis and DNA damage.   
Gene title Gene symbol p-Value
Fold-change 
(S vs. C)  a 
Apoptosis and survival_BAD phosphorylation
epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) EGFR 0.02 1.59
phosphoinositide-3-kinase, regulatory subunit 2 (beta) PIK3R2 0.04 1.23
protein kinase, cAMP-dependent, catalytic, gamma PRKACG 0.02 1.25
protein tyrosine phosphatase, non-receptor type 11 PTPN11 0.03       1.11
SHC (Src homology 2 domain containing)-transforming protein 1 SHC1 0.03 1.16
DNA damage_Role of SUMO in p53 regulation
CREB-binding protein CBP 0.01 1.31
SMT3 suppressor of mif two 3 homolog 1 (  S. cervisiae ) SUMO-1 0.03 1.17
ubiquitin-like modiﬁ  er activating enzyme 1 UBA1 0.04 1.14
Other genes involved in DNA damage and oxidative stress
HLA-B (major histocompatibility complex, class I, B)-associated transcript 3 BAT3/BAG6 0.01       1.21
calpain 9 CAPN9 0.05 1.15
calpain 10 CAPN10 0.02 1.14
clusterin CLU 0.02 2.02
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involvement of TGF-  β   signaling in the pathophysiology 
of schizophrenia in general (Miller et     al., 2011). Within 
the TGF- β  superfamily, we found that the canonical BMP 
signaling pathway was signiﬁ  cantly affected (  Ingenuity : 
p        0.003;   GeneGo :  p        0.005)  (Table  3a).  Speciﬁ  cally, 
we observed an up-regulation of   BMP7   and BMP recep-
tor 1A (  BMPR1A  ), in addition to changes in genes 
further downstream in the signaling cascade (Figures 3 
and Supplementary Figure 3 available online at http://
informahealthcare.com/doi/abs/10.3109/01677063.2014.
882918). Both the TFG-  β   and BMP canonical pathways 
propagate their signal via SMADs (Shi   &   Massague, 
2003) (Figures 3 and Supplementary Figure 3 available 
online at http://informahealthcare.com/doi/abs/10.3109/
01677063.2014.882918) and we found that   SMAD4   and 
  SMAD5   were up-regulated in schizophrenia. SMAD4 
is the central mediator of both of these signal transduc-
tion cascades and regulates the transcription of target 
genes (Ross   &   Hill, 2008). Furthermore, we observed 
an increase in the expression of cyclic adenosine mono-
phosphate (cAMP) response element-binding protein 
   Table 3d.   Signiﬁ  cantly affected genes associated with cytoskeletal and dendritic integrity.   
Gene title Gene symbol p-Value
Fold-change 
(S vs. C)  a 
actin, gamma 2, smooth muscle, enteric ACTG2 0.04 1.35
dystonin DST 0.03 1.25
major histocompatibility complex, class I, A HLA-A 0.02 1.86
integrin, beta 5 ITGB5 0.02 1.51
microtubule-associated protein 1 light chain 3 gamma MAP1LC3C 0.03 1.19
myosin IIIB MYO3B 0.01 1.13
tropomodulin 3 (ubiquitous) TMOD3 0.02       1.14
tubulin polymerization promoting protein TPPP 0.03       1.50
tubulin tyrosine ligase-like family, member 12 TTLL12 0.02 1.20
tubulin, alpha 4b (pseudogene) TUBA4B 0.02       1.17
spectrin, beta, non-erythrocytic 1 SPTBN1 0.05 1.20
    a S        schizophrenia;  C        control.   
  Figure 3.      Representative  diagram  of  TGF-    and BMP signaling 
pathways. Both TGF-  β   and BMP7 activate SMAD4 and CREB-
binding protein, a transcription co-activator of SMAD, leading 
to the transcription of target genes that inﬂ  uence extracellular 
matrix composition, apoptosis, and synaptic/cytoskeletal plas-
ticity.  BMPR1A        bone  morphogenetic  protein  receptor  type 
IA;  CBP        CREB-binding  protein;  SARA  (ZFYVE9)        zinc 
ﬁ  nger, FYVE domain containing 9; SMAD4           mothers  against 
decapentaplegic homolog 4. Genes up-regulated in schizophrenia 
are depicted by red arrows.   
  Figure 2.     Correlation analysis comparing fold-changes of selected 
genes determined by microarray and qRT-PCR. Comparison of 
fold-changes of differentially expressed genes within signaling 
pathways identiﬁ  ed as dysregulated in schizophrenia (  N         6 )  
and several randomly selected genes (  N         4)  determined  by 
microarray and qRT-PCR. BMP7           bone  morphogenetic  protein 
7;  BMPR1A            bone morphogenetic protein receptor type IA; 
CLU        clusterin;  HLA-A        major  histocompatibility  complex 
(MHC), class I, A; HPRT        hypoxanthine guanine phosphoribosyl 
transferase;  P2RY14        purinergic  receptor  P2Y,  G-protein 
coupled, 14; MCPH1            microcephalin  1;  SMAD4        mothers 
against decapentaplegic homolog 4; SMAD5           mothers  against 
decapentaplegic homolog 5; VCAN           versican.  Pyramidal Neurons in Schizophrenia  61
(CREB)-binding protein (CBP), a transcription co-acti-
vator of SMAD (Ohta et     al., 2008). Although not part 
of this particular canonical pathway, we noted a down-
regulation of   BMP5  , which also acts via the BMPR1A 
(Beck et     al., 2001). Of interest,   BMP5 ,   BMP7 ,   SMAD5 , 
and   CBP   were all found to be signiﬁ  cantly associated 
with schizophrenia in a recent genome-wide association 
study (Jia et     al., 2010), with both   TGFB1   and   SMAD5  
implicated as potential candidate genes in a linkage 
study (Zaharieva et     al., 2008). Finally, these pathways 
are known to regulate the integrity of ECM (Hyytiainen 
et     al., 2004; Smith   &   Strunz, 2005; Zhou et     al., 2003), 
apoptosis (Dhandapani  &  Brann, 2003), and cytoskeleton 
(Guo et   al., 1998; Moustakas  &  Heldin, 2008), raising the 
possibility that disturbances of genes that regulate these 
functions (see below) may in part represent downstream 
consequences of dysregulated TGF-  β /BMP  signaling.   
  ECM Regulation Is Altered in Schizophrenia 
  Gene networks related to ECM functionality, including 
altered cellular movement (p              0.03) and changes in adhe-
sion to the ﬁ  bronectin matrix (p            0.05),  were  altered  in 
schizophrenia (Table 3b). Speciﬁ  cally, a number of genes 
coding for chondroitin sulfate proteoglycans (CSPGs) 
were down-regulated. These include aggrecan, versican, 
leprecan, lumican, testican, and spondin1. In addition, we 
found changes in genes that encode matrix metallopepti-
dases (MMPs), which are enzymes that are involved in the 
breakdown and remodeling of ECM by the proteolysis of 
several ECM components, including the CSPGs (Rauch, 
2004). Speciﬁ  cally, we found an up-regulation of ADAM 
(a disintegrin and metallopeptidase) metallopeptidase with 
thrombospondin type 1 motif gene family (  ADAMTS1  
and   ADAMTS6  ), in addition to alterations in several other 
MMPs, in the schizophrenia samples (Table 3b). Together 
these data suggest that the decrease in ECM structural 
components, such as CSPGs, in addition to the alterations 
in the enzymes that regulate their proteolysis, contribute to 
the altered integrity of ECM (Ikeda et     al., 2009; Mauney 
et     al., 2013; Pantazopoulos et     al., 2010).    
  Apoptosis Regulation Is Altered in Schizophrenia 
  Two apoptosis canonical pathways were found to be 
dysregulated in schizophrenia (Table 3c). We noted 
predominantly an up-regulation of genes within the 
p53-regulated apoptosis pathway (  GeneGo  : p       0.03), 
suggesting pro-apoptotic events (Pietsch et     al., 2008), 
although the exact function of sumoylation of p53 
remains controversial (Melchior   &   Hengst, 2002). We 
also found changes in the expression of several genes 
associated with oxidative stress and DNA damage 
(Table 3c). Conversely, we saw increased expression of 
anti-apoptotic genes within the BCL2 (B-cell chronic 
lymphocytic leukemia [CLL]/lymphoma 2)-associated 
agonist of cell death (BAD) apoptosis survival pathway 
(  GeneGo :  p            0.03), which inhibits apoptosis through 
BAD phosphorylation (Bergmann, 2002). Interestingly, 
TGF-  β   signaling regulates BAD phosphorylation via the 
induction of anti-apoptotic proteins of the BCL-2 family 
(E. S. Kim et     al., 1998). Together these results appear to 
reﬂ  ect the complex interplay between the orchestrated 
molecular responses regulating apoptosis that may in 
part be mediated by TGF-  β   signaling.   
  Cytoskeletal Regulation Is Altered in Schizophrenia 
  We found signiﬁ  cant alterations in key biological func-
tions (  Ingenuity  ) related to the integrity of cytoskeleton. 
This included the organization of actin cytoskeleton 
(p        0.05)  and  actin  ﬁ   laments  (p        0.05),  coalignment  of 
neuroﬁ  laments and microﬁ   laments  (p        0.05)  and  redis-
tribution of F-actin (p              0.05). We also noted changes in 
genes encoding cytoskeletal components, such as tubulin 
and myosin (Table 3d). Finally, we observed that the 
integrin   β  5 receptor was up-regulated in schizophrenia. 
Integrin signaling is the major signaling pathway that 
mediates the interaction between ECM and the assembly 
of actin ﬁ  laments that is necessary for cytoskeletal modi-
ﬁ  cation (Giancotti   &   Ruoslahti, 1999; Shi   &   Ethell, 2006; 
Wozniak  et    al.,  2004).    
 miRNA  Proﬁ  ling by Megaplex miRNA TaqMan 
Arrays 
  miRNA expression levels were normalized to the 
endogenous sno-RNA MammU6, whose levels were 
unchanged between control and schizophrenia samples 
for both the Human miRNA A and B Cards (mean     
SEM:  30.63        0.35  and  31.72        0.72,  respectively).  Out 
of the 754 miRNAs investigated, analysis of variance 
(ANOVA) revealed 10 differentially expressed miRNAs 
(p            0.05; Table 4). Many of these miRNAs are known 
to be expressed in the brain (Baskerville   &   Bartel, 2005; 
Landgraf et     al., 2007), with some identiﬁ  ed as being spe-
ciﬁ  cally localized in mammalian cortical neurons (e.g., 
miR-30b and miR-328) (J. Kim et     al., 2004). A number 
of the differentially expressed miRNAs also correspond 
with previous studies on postmortem schizophrenia 
samples, including miR-150 (J. Kim et     al., 2004), miR-
328 (Santarelli et     al., 2011), and miR-30b (Mellios et     al., 
2012; Perkins et     al., 2007), with the caveat that all of 
the previously published miRNA proﬁ  ling results were 
based on RNAs extracted from homogenized gray matter. 
Interestingly, enrichment analysis of the predicted target 
genes of the differentially expressed miRNAs revealed 
that the overrepresented signaling pathways included 62  C. Y. Pietersen et al.
many of the pathways identiﬁ   ed by microarray as 
differentially regulated in schizophrenia, such as TGF-  β  
signaling, ECM composition, apoptosis, and cytoskeleton 
(Table 5, Supplementary Table 3 available online at http://
informahealthcare.com/doi/abs/10.3109/01677063.2014.
882918). The speciﬁ  c genes that were found by microar-
ray to be differentially expressed in schizophrenia and are 
also the predicted targets of the differentially expressed 
miRNAs are shown in Supplementary Table 4 available 
online at http://informahealthcare.com/doi/abs/10.3109/
01677063.2014.882918.    
 DISCUSSION 
  In order to understand the pathophysiology of schizo-
phrenia, which is a manifestation of functional distur-
bances of cortical circuits characterized by neuronal 
type  –  dependent connectional complexity, it is necessary 
to deﬁ   ne the molecular pathology of the illness in a 
neuronal  type – speciﬁ  c manner. In this context, previous 
gene expression proﬁ  ling studies of the cerebral cortex 
in schizophrenia have largely relied on the extraction of 
RNA from homogenized gray matter. Interpretation of 
these results can be difﬁ  cult due to the profound cellular 
heterogeneity of the cerebral cortex, as gene expression 
changes that may be conﬁ   ned to a subset of neurons 
can be obscured, especially if transcript abundance is 
low or if speciﬁ   c transcripts are preferentially local-
ized to cell types that are relatively uncommon. In this 
study, by combining LCM with mRNA proﬁ  ling,  we 
circumvented these potential problems and identiﬁ  ed 
molecular cascades that appear to be dysregulated in 
layer 3 pyramidal neurons in the STG in schizophrenia. 
Speciﬁ  cally, our data revealed that a number of genes 
within the TGF-  β   superfamily, especially those that 
regulate BMP signaling, were differentially expressed 
in subjects with schizophrenia. In addition, we identiﬁ  ed 
abnormalities in genes that regulate apoptosis, cytoskele-
tal plasticity, and ECM, that may, at least in part, represent 
downstream consequences of TGF-  β   signaling dysregula-
tion. We should also note that the majority (61%) of these 
genes, with some exceptions, such as those that regulate 
ECM, were found to be up-regulated. In contrast, previous 
studies interrogating the expression of mRNA extracted 
from homogenized gray matter have revealed an overall 
decrease in gene expression (Iwamoto  &  Kato, 2006), and, 
for the most part, these genes do not overlap with genes 
identiﬁ  ed in the present study. These differential ﬁ  ndings, 
in our opinion, highlight the argument that neuronal type  – 
speciﬁ  c gene expression alterations and thus the molecular 
pathophysiology of the illness in terms of cortical neuronal 
circuit dysfunction cannot necessarily be inferred from the 
interrogation of expression of transcripts obtained from 
homogenized cortical tissue. In more speciﬁ  c quantitative 
terms, approximately 84% of the volume of the cortex, 
excluding layer 1, contains glias, neuropil, which comprises 
axonal elements, dendrites and dendritic spines, and vascu-
lar elements such as blood vessels and related cellular com-
ponents, including endothelial cells and various blood cells 
(Braitenberg   &   Schuz, 1998), and the abundance of many 
transcripts can vary in a compartment-speciﬁ  c  manner 
(Cajigas et     al., 2012). Of the remaining 16% of the volume 
that contains neuronal bodies in layers 2  –  6, approximately 
80% of them are pyramidal neurons and roughly 16% (i.e., 
80% divided by 5 layers) are from layer 3. In other words, 
layer 3 pyramidal neurons represent only about 3% (i.e., 
16% times 16%) of the entire volume of cortical gray mat-
ter. As such, it is difﬁ  cult to envision that gene expression 
changes that may be restricted to this neuronal population 
can be readily discerned by studying RNA obtained from 
homogenization of the entire gray matter. This would argu-
ably be especially true for the less abundant cell types, such 
as the various subsets of inhibitory neurons, including those 
that were examined in the accompanying study, the parval-
bumin (PV)-containing neurons (Pietersen et     al. 2014).   
   Table 5.   Overrepressented KEGG pathways based on enrichment analysis of the predicted target 
genes of the differentially expressed miRNAs.   
Pathway Enrichment statistics
TGF-  β   signaling  pathway C        155;  O        63;  E        8.75;  R        7.20;  rawP        1.27e-37;  adjP        1.45e-35
Focal  adhesion C        201;  O        48;  E        11.35;  R        4.23;  rawP        9.92e-18;  adjP        1.46e-16
Regulation of actin cytoskeleton C           143;  O        37;  E        8.07;  R        4.58;  rawP        3.41e-15;  adjP        4.32e-14
Apoptosis C        82;  O        20;  E        4.63;  R        4.32;  rawP        2.12e-08;  adjP        8.06e-08
ECM-receptor  interaction C        84;  O        16;  E        4.74;  R        3.37;  rawP        1.67e-05;  adjP        4.63e-05
   Table 4.   Differentially expressed miRNAs in schizophrenia.   
miRNA assay name p-Value
Log  2  
fold-change
hsa-miR-1243-002854 0.03       0.41
hsa-miR-126-4395339 0.03 1.84
hsa-miR-150-4373127 0.05       0.96
hsa-miR-30b-4373290 0.02 4.64
hsa-miR-328-4373049       0.001 2.82
hsa-miR-378-002243 0.04       0.31
hsa-miR-520d-3p-002743 0.01 0.12
hsa-miR-628-5p-4395544 0.03       1.05
hsa-miR-875-5p-002203 0.04       0.41
hsa-miR-99b-4373007 0.04 2.77Pyramidal Neurons in Schizophrenia  63
  Methodological Considerations and Limitations 
  The goal of this study was to delineate the gene expres-
sion proﬁ  le of layer 3 pyramidal neurons in schizophrenia 
in order to gain insight into the molecular basis of corti-
cal circuit dysfunction. In this context, it should be noted 
that obtaining RNA from a truly homogeneous source 
from postmortem human brains, given the technologies 
that are available at the present time, is probably not 
achievable. For instance, when capturing pyramidal neu-
rons, it would have been inevitable to include additional 
elements, such as the perineuronal oligodendrocytes, 
GABA(  γ  -aminobutyric acid)ergic axon terminals that 
innervate the perisomatic region of pyramidal neurons, 
etc. In fact, we found that the mRNA for the gene that 
encodes the 65-kDa isoform of the GABA-synthesizing 
enzyme glutamic acid decarboxylase (  GAD2  ) was sig-
niﬁ  cantly down-regulated by 1.9-fold in the schizophre-
nia subjects (Supplementary Table 3 available online at 
http://informahealthcare.com/doi/abs/10.3109/01677063.
2014.882918). This is not a type I error, as qRT-PCR 
conﬁ  rmed the presence of this transcript in our samples 
and its down-regulation by 3.1-fold. Because   GAD2   is 
clearly not expressed in pyramidal neurons and because 
our sampling approach excludes the possibility of sys-
tematic inclusion of GABAergic neurons in our samples, 
the   GAD2   mRNA in the samples most likely came from 
the GABAergic axon terminals innervating the pyrami-
dal cell bodies. However, deﬁ  nitive conﬁ  rmation of the 
presence of mRNA in axonal terminals in the human 
brain would be technically challenging. 
  Another consideration is that due to the labor-
intensive nature of this methodological approach and the 
associated costs, the sample size of this study is small. 
This may have increased the likelihood of type II error. 
Although to a certain extent type I error can be addressed 
by means of validation (e.g., by qRT-PCR), type II error 
can only be minimized by increasing sample size. Finally, 
because the amount of RNA available for each sample 
was limited, the number of genes we were able to vali-
date by qRT-PCR is small. For the same reason, we only 
used one housekeeping gene for normalization and sam-
ples were run in duplicate instead of triplicate. Because 
of these limitations and caveats, we consider this study 
proof-of-principle and our ﬁ  ndings preliminary; it would 
therefore be critical to conﬁ  rm these ﬁ  ndings in a differ-
ent and ideally larger cohort of subjects in future stud-
ies. Ultimately, true validation of microarray observations 
will have to be achieved by experimentally demonstrating 
mechanistic links between the disturbances of genes and 
pathways identiﬁ  ed as altered in schizophrenia and known 
cellular and clinical phenotypes of the illness, such as 
decreased spine density on pyramidal neurons (Glantz   &   
Lewis, 2000; Sweet et     al., 2009) or disturbances of ECM 
integrity (Pantazopoulos et     al., 2010), and neurocognitive 
deﬁ  cits (Barch et     al., 2003; Bowie   &   Harvey, 2005; Cho 
et     al., 2006) or gamma oscillation disturbances (Cho et     al., 
2006; Kwon et     al., 1999; Spencer et     al., 2004; Uhlhaas 
  &   Singer, 2010), respectively. In fact, this is exactly how 
postmortem microarray studies can uniquely contribute to 
the understanding of the pathophysiology of human psy-
chiatric disorders; that is, they can inspire the conceptu-
alization of novel hypotheses of disease mechanisms that 
can then be experimentally interrogated either in vitro or 
in animal systems.     
  Functional Considerations of Up-regulation of TGF-  b  
and BMP Signaling in Schizophrenia   
  Apoptosis and Dendritic Atrophy 
  Up-regulation of TGF-  β   signaling typically represents a 
homeostatic response under a wide variety of pathologi-
cal conditions, such as excitotoxicity (Chou et     al., 2006; 
Dhandapani   &   Brann, 2003; Gabriel et     al., 2003; Klempt 
et     al., 1992; Petegnief et     al., 2003). In schizophrenia, 
there has been compelling evidence indicating that the 
PV-containing fast-spiking inhibitory neurons, which 
confer perisomatic and axo-axonic inhibition to pyramidal 
neurons, are functionally disturbed (Lewis et     al., 2005). 
Speciﬁ  cally, inhibition furnished by these neurons may 
be deﬁ  cient, as the mRNA for the 67-kDa isoform of the 
GABA-synthesizing enzyme (  GAD1  ) appears to be unde-
tectable in close to half of the populations of PV neurons 
in schizophrenia (Hashimoto et     al., 2003). In addition, 
the expression of the   N -methyl- D  -aspartate (NMDA) glu-
tamate receptor NR2A subunit mRNA in some of these 
neurons has also been shown to be signiﬁ  cantly decreased 
(Bitanihirwe et     al., 2009), suggesting that excitatory 
inputs to PV neurons may also be impaired. Together 
these ﬁ  ndings support the idea that pyramidal neurons that 
are postsynaptic to PV neurons may become hyperactive 
as a result of disinhibition of PV neurons (Homayoun   &   
Moghaddam, 2007; Kinney et     al., 2006; Olney   &   Farber, 
1995). In this context, the observed up-regulation of TGF- β  
signaling may represent a homeostatic or neuroprotective 
response of pyramidal neurons to such excitotoxic insult 
(Figure 4) (Gabriel et   al., 2003; Petegnief et   al., 2003). One 
mechanism that TGF-  β   signaling could exert homeostatic 
effects is through the regulation of BAD phosphorylation 
pathway via the induction of anti-apoptotic proteins of the 
BCL-2 family (E. S. Kim et     al., 1998; Prehn et     al., 1994). 
In line with other postmortem studies indicating increased 
expression of anti-apoptotic genes in schizophrenia, such 
as BCL-2 (Benes, 2006; Benes et   al., 2006), we also noted 
in our study an up-regulation of several genes within this 
pathway. Conversely, although we found an up-regulation 
of several pro-apoptotic genes within the p53-regulated 
pro-apoptosis pathway, e.g.,   SUMO-1   (small ubiquitin 64  C. Y. Pietersen et al.
related modiﬁ  er precursor),   UBA1   (ubiquitin-like modi-
ﬁ  er activating enzyme 1), and   CBP  , expression of   TP53 , 
which encodes p53, the key initiator of apoptosis, was 
unaltered. 
  Although large-scale pyramidal cell death does not 
occur in schizophrenia,   “  nonlethal  ”   apoptosis can lead to 
neuronal injury in the form of dendritic atrophy (Glantz 
et     al., 2006). For example, chronic glutamate excess has 
been shown to lead to a 20% reduction in primary den-
dritic length without causing cell death (Esquenazi et     al., 
2002). The integrity of dendritic architecture depends 
on coordinated activities of various cytoskeletal com-
ponents (Svitkina et     al., 2010). Our results indicate that 
several cytoskeletal genes, including actin, tubulin, and 
microtubules, are dysregulated in schizophrenia. BMP 
signaling, particularly BMP7, has also been shown to 
affect dendrite formation in cortical neurons (Guo et     al., 
1998; Horbinski et     al., 2002; Le Roux et     al., 1999), 
through both the remodeling of the actin cytoskeleton 
(Lee-Hoeﬂ  ich et     al., 2004) and the stabilization of micro-
tubules (Podkowa et     al., 2010). Of interest, BMP7 has 
also been shown to attenuate the reduction of primary 
dendrites exposed to glutamate excitotoxicity, suggest-
ing a neuroprotective response (Esquenazi et     al., 2002). 
Considering all of these ﬁ  ndings together, up-regulation 
of TGF-  β  /BMP signaling may represent a molecular 
snapshot of the internal homeostasis of these neurons in 
response to disinhibition-induced excitotoxic injury.     
 ECM  Disturbances 
  CSPGs are critical components of perineuronal nets 
(PNNs) (Figure 5A), which are ECM structures that 
enwrap the cell body and perisomatic region of various 
types of neurons, including PV and pyramidal neurons 
(Frischknecht   &   Seidenbecher, 2008). They are believed 
to originate predominantly from glial cells and are 
secreted into the extracellular space (Morgenstern et     al., 
2002; Pantazopoulos et     al., 2008). Using biotin-labeled 
lectin from  Wisteria ﬂ  oribunda  agglutinin (WFA) to label 
CSPGs, it has recently been found that, in the human 
amygdala, CSPG-containing cells were virtually exclu-
sively astrocytes (Pantazopoulos et     al., 2008, 2010). At 
the same time, the density of PNNs in the amygdala has 
been found to be signiﬁ  cantly decreased in schizophrenia 
(Pantazopoulos et     al., 2010), which may be a result of 
impaired secretion and/or production of CSPGs by astro-
cytes (Pantazopoulos et     al., 2010). In the present study, 
however, our data indicate that the transcripts of many 
of the genes that encode CSPGs are present in pyramidal 
neurons in the STG. Consistent with this, it has recently 
been shown that one of the CSPGs, versican, is localized 
to the somata and dendrites of pyramidal neurons in the 
mouse cerebral cortex (Horii-Hayashi et     al., 2008). Cell 
culture studies have also shown that the production of 
some of the CSPGs, such as aggregan, may be glia inde-
pendent (Giamanco   &   Matthews, 2012). Furthermore, 
using WFA histochemistry, we have found that many 
of the cells that express CSPGs in the human cerebral 
cortex appear to be neurons, not astrocytes (Ikeda et     al., 
2009) (Figure 5B). Hence, cellular mechanisms of 
CSPG production and/or secretion may differ between 
the cortex and subcortical structures. In the present 
study, we found that many of the CSPG transcripts in 
  Figure 4.         Hypothetical model of pyramidal cell dysfunction in 
schizophrenia. It is hypothesized that as a result of disinhibition-
induced excitotoxic insult (see text for details), TGF  β   signaling 
within pyramidal neurons is up-regulated, which may contribute 
to extracellular matrix abnormalities, dysregulated apoptosis, 
and impaired synaptic and cytoskeletal plasticity. Shown in this 
highly simpliﬁ  ed diagram are some of the hub genes that can be 
targeted in future experiments in the testing of this hypothesis.   
  Figure 5.      Wisteria  ﬂ  oribunda   agglutinin (WFA) histochemical 
labeling of chondroitin sulfate proteoglycans (CSPGs) in 
the human cerebral cortex. (  A  ) CSPG-rich perineuronal nets 
(  arrowheads ).  ( B  ) WFA also labeled intracellular CSPGs 
(  arrowhead ).  Scale  bars        5    μ m  ( A   and   B ).  Pyramidal Neurons in Schizophrenia  65
pyramidal neurons were signiﬁ  cantly down-regulated in 
schizophrenia (Table 3b). Consistent with this observa-
tion and the aforementioned ﬁ  nding in the amygdala 
(Pantazopoulos et     al., 2010), the density of PNNs in the 
prefrontal cortex has also been found to be decreased 
in schizophrenia (Mauney et     al., 2013). A decrease in 
PNNs may render synaptic structures more vulnerable 
to alterations, contributing to reduced synaptic connec-
tivities. It is of interest to note that TGF-  β   signaling is 
known to play a key role in regulating CSPGs (Asher 
et     al., 2002). However, activation of TGF-  β   signaling 
typically leads to increased CSPG production (Asher 
et     al., 2000, 2002), but we observed primarily a down-
regulation of CSPG mRNAs. Further investigation is 
therefore needed to elucidate the precise relationship, if 
any, between the up-regulation of TGF-  β   signaling and 
the dysregulation of CSPGs in schizophrenia.       
  Altered miRNA Expression in Schizophrenia 
 In addition to alterations in gene expression and biological 
pathways, we also noted changes in the posttranscriptional 
regulatory environment, characterized by alterations in 
miRNA expression. The number of miRNAs identiﬁ  ed 
in this study is relatively small, but in the same order 
of magnitude as found in previous studies investigating 
miRNA expression in the cerebral cortex in schizophrenia 
(Beveridge et     al., 2008; Moreau et     al., 2011; Santarelli 
et     al., 2011). However, direct comparison of our data with 
those of the previous studies may not be appropriate, as 
all of these studies examined RNA extracted from homog-
enized cortical gray matter. 
  Results of pathway analysis of the predicted target 
genes of the differentially expressed miRNAs correlate 
highly with the dysregulated biological pathways identi-
ﬁ  ed by mRNA expression proﬁ  ling, such as TGF-  β   sig-
naling, regulation of actin cytoskeleton, ECM-receptor 
interaction, and apoptosis (Table 5), in addition to other 
pathways that have also been associated with schizophre-
nia, such as mitogen-activated protein kinase (MAPK) 
signaling, neurotrophin signaling, axon guidance, and 
WNT signaling. These data raise an intriguing possibility 
that the pathophysiology of pyramidal cell dysfunction in 
schizophrenia may in part be mediated by the concerted 
dysregulation of gene network functions as a result of 
the altered expression of a relatively small number of 
miRNAs.    
 CONCLUSION 
  We have identiﬁ  ed molecular pathways that appear to 
be altered in layer 3 pyramidal neurons in the STG in 
schizophrenia. These ﬁ  ndings provide a neurobiological 
foundation upon which experimental manipulation of 
the expression of the differentially expressed genes may 
allow us to begin to characterize the molecular architec-
tures that underlie pyramidal cell dysfunction in schizo-
phrenia. For instance, based on our ﬁ  ndings, one might 
hypothesize that neurons derived from induced pluripo-
tent stem cells from patients with schizophrenia may be 
particularly vulnerable to oxidative stress, which may 
then lead to dysregulated TGF-  β  /BMP signaling and 
downstream consequences, such as compromised extra-
cellular matrix, hypoplastic dendritic spines, etc. An 
alternative approach may involve overexpressing genes 
related to the TGF-  β  /BMP pathway using pyramidal 
cell – speciﬁ  c promoters in   in vivo   systems to see if this 
may result in similar molecular pathologies. Hence, this 
  “  reverse translational strategy  ”   circumvents the tradi-
tional difﬁ  culties of studying the biology of psychiatric 
disorders due to the inaccessibility of the living human 
brain and may ultimately lead to deeper understanding 
of the pathogenetic mechanisms of these devastating, 
uniquely human disorders.                   
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